Table 1.
Protocol initiator, source of founding, nature of BDR, organ and state
| All | BF | OT | p value | |
|---|---|---|---|---|
| (n = 245, 100 %) | (n = 147, 60 %)c | (n = 98, 40 %)d | ||
| Protocol initiator | ||||
| Academic | 176 (71.8 %) | 120 (81.6 %) | 56 (57.1 %) | <0.001 |
| Collaborative Groups | 42 (17.1 %) | 11 (7.5 %) | 31 (31.6 %) | |
| Industry | 15 (6.1 %) | 13 (8.8 %) | 2 (2.0 %) | |
| NIH | 12 (4.9 %) | 3 (2.0 %) | 9 (9.2 %) | |
| Source of funding | ||||
| Academic | 145 (59.2 %) | 99 (67.3 %) | 46 (46.9 %) | <0.001 |
| Collaborative Groups | 13 (5.3 %) | 2 (1.4 %) | 11 (11.2 %) | |
| Industry | 30 (12.2 %) | 25 (17.0 %) | 5 (5.1 %) | |
| NIH | 56 (22.9 %) | 20 (13.6 %) | 36 (36.7 %) | |
| Public-private part. | 1 (0.4 %) | 1 (0.7 %) | 0 (0.0 %) | |
| Type of BDRa | ||||
| Not definedb | 83 (33.9 %) | 30 (20.4 %) | 53 (54.1 %) | <0.001 |
| HDR | 75 (46.3 %) | 53 (45.3 %) | 22 (48.9 %) | 0.001 |
| HDR/LDR | 16 (9.9 %) | 6 (5.1 %) | 10 (22.2 %) | |
| HDR/PDR | 2 (1.2 %) | 2 (1.7 %) | 0 (0.0 %) | |
| LDR | 68 (42.0 %) | 56 (47.9 %) | 12 (26.7 %) | |
| PDR | 1 (0.6 %) | 0 (0.0 %) | 1 (2.2 %) | |
| Country | ||||
| USA | 144 (58.8 %) | 85 (57.8 %) | 59 (60.2 %) | 0.219 |
| Canada | 27 (11.0 %) | 20 (13.6 %) | 7 (7.1 %) | |
| France | 10 (4.1 %) | 6 (4.1 %) | 4 (4.1 %) | |
| China | 10 (4.1 %) | 7 (4.8 %) | 3 (3.1 %) | |
| Germany | 10 (4.1 %) | 8 (5.4 %) | 2 (2.0 %) | |
| Other | 44 (18.0 %) | 21 (14.3 %) | 23 (23.5 %) | |
| Organ | ||||
| Prostate | 80 (32.7 %) | 59 (40.1 %) | 21 (21.4 %) | <0.001 |
| Cervix uteri | 54 (22.0 %) | 10 (6.8 %) | 44 (44.9 %) | |
| Breast | 29 (11.8 %) | 25 (17.0 %) | 4 (4.1 %) | |
| Uterus | 14 (5.7 %) | 5 (3.4 %) | 9 (9.2 %) | |
| Other | 68 (27.8 %) | 48 (32.7 %) | 20 (20.4 %) |
a BDR brachytherapy dose rate, HDR high dose rate, LDR low dose rate, PDR pulse dose rate
bPercentage of total number per column
cBrachytherapy in focus
dOther trials